Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse

详细信息    查看全文

• 作者：Jessica L. Billings ; Dominic J. Hare ; Milawaty Nurjono ; Irene Volitakis ; Robert A. Cherny ; Ashley I. Bush ; Paul A. Adlard ; David I. Finkelstein
• 刊名：ACS Chemical Neuroscience
• 出版年：2016
• 出版时间：March 16, 2016
• 年：2016
• 卷：7
• 期：3
• 页码：360-366
• 全文大小：397K
• ISSN：1948-7193

文摘

Increased nigral iron (Fe) is a cardinal feature of Parkinson’s disease, as is the accumulation of aggregates comprising α-synuclein. We used wild-type mice and transgenic mice overexpressing the human A53T mutation to α-synuclein to examine the influence of increased Fe (days 10–17 postpartum) on the parkinsonian development phenotype of these animals (including abnormal nigral Fe levels and deficits in both cell numbers and locomotor activity), and to explore the impact of the Fe chelator clioquinol in the model. Both untreated and Fe-loaded A53T mice showed similar levels of nigral cell loss, though 5 months of clioquinol treatment was only able to prevent the loss in the non-Fe-loaded A53T group. Iron levels in the Fe-loaded A53T mice returned to normal at 8 months, though effects of dopamine denervation remained, demonstrated by limited locomotor activity and sustained neuron loss. These data suggest that Fe exposure during a critical developmental window, combined with the overexpression mutant α-synuclein, presents a disease phenotype resistant to intervention using clioquinol later in life.